ANI Pharmaceuticals Inc (ANIP) Stock
Fundamentals
Recent news

ANIP's Cortrophin Guidance Cut Raises the Bar for Second-Half Growth
ANIP's Cortrophin Guidance Cut Raises the Bar for Second-Half Growth
ANIP

Should You Buy ANIP as Low Valuation Meets Cortrophin Execution Risk?
Should You Buy ANIP as Low Valuation Meets Cortrophin Execution Risk?
ANIP

ANIP Tops Q2 Earnings, Stock Down on Cortrophin Sales View Cut
ANIP Tops Q2 Earnings, Stock Down on Cortrophin Sales View Cut
ANIP

Compared to Estimates, ANI (ANIP) Q2 Earnings: A Look at Key Metrics
Compared to Estimates, ANI (ANIP) Q2 Earnings: A Look at Key Metrics
ANIP
Technicals
Analyst Ratings
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
% positive news of 10 articles
published over the past 14 days
Latest news

ANIP's Cortrophin Guidance Cut Raises the Bar for Second-Half Growth
ANIP's Cortrophin Guidance Cut Raises the Bar for Second-Half Growth
ANIP

Should You Buy ANIP as Low Valuation Meets Cortrophin Execution Risk?
Should You Buy ANIP as Low Valuation Meets Cortrophin Execution Risk?
ANIP

ANIP Tops Q2 Earnings, Stock Down on Cortrophin Sales View Cut
ANIP Tops Q2 Earnings, Stock Down on Cortrophin Sales View Cut
ANIP

Compared to Estimates, ANI (ANIP) Q2 Earnings: A Look at Key Metrics
Compared to Estimates, ANI (ANIP) Q2 Earnings: A Look at Key Metrics
ANIP

ANI Pharmaceuticals Q2 Earnings Call Highlights
ANI Pharmaceuticals Q2 Earnings Call Highlights
ANIP

ANI Pharmaceuticals (ANIP) Q2 Earnings and Revenues Beat Estimates
ANI Pharmaceuticals (ANIP) Q2 Earnings and Revenues Beat Estimates
ANIP

ANI Pharmaceuticals (ANIP) Reports Next Week: Wall Street Expects Earnings Growth
ANI Pharmaceuticals (ANIP) Reports Next Week: Wall Street Expects Earnings Growth
ANIP

Trump's generic drug tariffs: What they could mean for medicine prices, manufacturers and supply
Trump's generic drug tariffs: What they could mean for medicine prices, manufacturers and supply
ANIP

ANI Pharmaceuticals reports Phase 4 data for uveitis eye implant
ANI Pharmaceuticals reports Phase 4 data for uveitis eye implant
ANIP

ANI Pharmaceuticals' CFO Sold $285,000 in Stock After a 32% Run
ANI Pharmaceuticals' CFO Sold $285,000 in Stock After a 32% Run
ANIP
About ANI Pharmaceuticals Inc
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid-dose products. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended-release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. The company operates in two segments which include Rare Diseases and Brands, Generics, and Others. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Nikhil Lalwani | President, CEO & Director | 1978 |
| Mr. Stephen P. Carey | Senior VP of Finance & CFO | 1971 |
| Ms. Meredith W. Cook J.D. | Senior VP, General Counsel & Corporate Secretary | 1974 |
| Mr. Christopher K. Mutz | Senior VP & Head of Rare Disease | 1972 |
| Mr. Ori Gutwerg | Senior Vice President of Generics | 1975 |
| Mr. Muthusamy Shanmugam MS R.Ph. | Head of R&D and COO of New Jersey Operations | 1968 |
| Ms. Irina Rivkind Koffler | Vice President of Investor Relations | — |
| Ms. Elizabeth Powell J.D. | Chief Compliance Officer & Head of Legal of Rare Disease | — |
| Mr. Chad Gassert | Senior Vice President of Corporate Development & Strategy | 1976 |
| Ms. Krista L. Davis | Senior VP & Chief Human Resources Officer | 1973 |
Fundamentals
Valuation
Earnings Per Share
Income Statement
Dividend
Solvency
Technicals
What the experts say
3 Wall Street Analyst Ratings
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -3.4 | +11.3 | -26.4 | +14.0 | ||||||||
| 2022 | -14.3 | -4.8 | -23.8 | +2.9 | +0.3 | -2.8 | +8.6 | +9.2 | -13.1 | +21.0 | +7.6 | +3.6 |
| 2023 | +11.7 | -5.6 | -9.4 | -2.8 | +18.4 | +16.0 | -2.7 | +26.8 | -10.1 | +8.6 | -19.2 | +9.0 |
| 2024 | -2.4 | +19.7 | +2.9 | -2.8 | -2.4 | +0.4 | +3.6 | -0.2 | -5.3 | -3.7 | -1.6 | -4.5 |
| 2025 | +5.8 | +6.9 | +14.5 | +4.1 | -16.9 | +5.4 | -0.3 | +46.3 | -2.7 | +0.5 | -9.8 | -6.5 |
| 2026 | +4.4 | -7.6 | +2.2 | +4.6 | -2.3 | +7.9 | -4.6 | -8.5 | +2.9 |



